Ocrelizumab, a novel anti-CD20 monoclonal antibody, is set to enter phase III testing in MS, according to industry newsletter FierceBiotech (www.fiercebiotech.com). The announcement was made at an investor event hosted by Roche. The drug was developed by Genentech, a subsidiary of Roche, and Biogen Idec.
Latest News
Dalfampridine may improve walking ability: phase III results
March 9, 2011A phase III trial of dalfampridine, or 4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502).
Mirtazapine, paroxetine associated with greater risk of weight gain
March 9, 2011The first meta-analysis of the effect of antidepressants on body weight has found that mirtazapine, paroxetine and amitriptyline are associated with a greater risk of weight gain (Serretti & Mandelli. J Clin Psychiatry 2010; 71: 1259-1272). Fluoxetine and bupropion were associated with some weight loss.
Deep brain stimulation: consensus recommendations
March 9, 2011An international consortium has published its recommendations on issues relating to deep brain stimulation (DBS) in patients with Parkinson’s disease (Bronstein et al. Arch Neurol 2010; epublished October 11, 2010).